Praziquantel, mefloquine-praziquantel, and mefloquine-artesunate-praziquantel against Schistosoma haematobium: a randomized, exploratory, open-label trial
about
Efficacy and Safety of Moxidectin, Synriam, Synriam-Praziquantel versus Praziquantel against Schistosoma haematobium and S. mansoni Infections: A Randomized, Exploratory Phase 2 TrialImpact of Schistosoma mansoni on malaria transmission in Sub-Saharan AfricaBuilding a global schistosomiasis alliance: an opportunity to join forces to fight inequality and rural povertyControlling schistosomiasis with praziquantel: How much longer without a viable alternative?Natural products with antischistosomal activity.Efficacy and safety of praziquantel 40 mg/kg in preschool-aged and school-aged children: a meta-analysis.Repurposing pharma assets: an accelerated mechanism for strengthening the schistosomiasis drug development pipeline.Something old, something new: is praziquantel enough for schistosomiasis control?Health & Demographic Surveillance System Profile: The Taabo Health and Demographic Surveillance System, Côte d'Ivoire.Interactions between mefloquine and the anti-fibrotic drug silymarin on Schistosoma mansoni infections in mice.Antischistosomal agents: state of art and perspectives.Schistosomiasis therapeutics: whats in the pipeline?Heterogeneity in the in vitro susceptibility of Loa loa microfilariae to drugs commonly used in parasitological infections.Drug Repurposing for Schistosomiasis: Combinations of Drugs or Biomolecules.Prevalence and intensity of Schistosoma haematobium infection among schoolchildren in central Zambia before and after mass treatment with a single dose of praziquantel.Challenges and recent progress in drug discovery for tropical diseases
P2860
Q28389462-5B5AAB12-3D24-456C-812E-63237866F308Q28543825-2A81758D-46E2-4082-BF5D-01793668AD9DQ30235143-72853787-AF41-43A0-A64B-F06E496EEB0AQ37726920-F17F9E5E-508E-40DD-92CB-6698C7C2B56BQ38495064-F3931A94-6E4B-46F6-ADD9-811A7A19CEB2Q38997065-DB3F531A-1154-4E85-BF49-E52F6AF77202Q39004171-6255F709-46DC-424E-A1A4-9BF5DD47858FQ39004194-E68C232B-A44B-46D2-B76A-7DCE114D3D59Q39144968-F8B7003D-8515-46E0-8DD2-12EF3AD95B22Q40812997-3B4836E9-1F44-414E-A572-6040604DB470Q47784982-12C44FB7-313E-4393-AC08-AE1AB79CDFD6Q50966400-A92882C6-B5F6-4C88-8643-5E50D413C0FDQ52609400-B9FC5C36-7FBD-4BE7-A86B-0268A5EF0C6FQ52699502-EFBC7864-39C5-4DC8-A615-639BF4B55381Q55342111-7E7197A4-3F56-425F-84CA-FC369AFB664EQ59073293-3649266A-CA53-4496-91A6-006AFC69144F
P2860
Praziquantel, mefloquine-praziquantel, and mefloquine-artesunate-praziquantel against Schistosoma haematobium: a randomized, exploratory, open-label trial
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Praziquantel, mefloquine-prazi ...... exploratory, open-label trial
@ast
Praziquantel, mefloquine-prazi ...... exploratory, open-label trial
@en
Praziquantel, mefloquine-prazi ...... exploratory, open-label trial
@nl
type
label
Praziquantel, mefloquine-prazi ...... exploratory, open-label trial
@ast
Praziquantel, mefloquine-prazi ...... exploratory, open-label trial
@en
Praziquantel, mefloquine-prazi ...... exploratory, open-label trial
@nl
prefLabel
Praziquantel, mefloquine-prazi ...... exploratory, open-label trial
@ast
Praziquantel, mefloquine-prazi ...... exploratory, open-label trial
@en
Praziquantel, mefloquine-prazi ...... exploratory, open-label trial
@nl
P2093
P2860
P50
P921
P3181
P1476
Praziquantel, mefloquine-prazi ...... exploratory, open-label trial
@en
P2093
Kigbafori D Silué
Lukas K Adiossan
N'Chou Monsan
Nicaise A N'Guessan
P2860
P3181
P356
10.1371/JOURNAL.PNTD.0002975
P407
P577
2014-07-01T00:00:00Z